| Literature DB >> 29391919 |
Anne Steinemann1,2,3.
Abstract
Fragranced consumer products, such as cleaning supplies, air fresheners, and personal care products, can emit a range of air pollutants and trigger adverse health effects. This study investigates the prevalence and types of effects of fragranced products on asthmatics in the American population. Using a nationally representative sample (n = 1137), data were collected with an on-line survey of adults in the USA, of which 26.8% responded as being medically diagnosed with asthma or an asthma-like condition. Results indicate that 64.3% of asthmatics report one or more types of adverse health effects from fragranced products, including respiratory problems (43.3%), migraine headaches (28.2%), and asthma attacks (27.9%). Overall, asthmatics were more likely to experience adverse health effects from fragranced products than non-asthmatics (prevalence odds ratio [POR] 5.76; 95% confidence interval [CI] 4.34-7.64). In particular, 41.0% of asthmatics report health problems from air fresheners or deodorizers, 28.9% from scented laundry products coming from a dryer vent, 42.3% from being in a room cleaned with scented products, and 46.2% from being near someone wearing a fragranced product. Of these effects, 62.8% would be considered disabling under the definition of the Americans with Disabilities Act. Yet 99.3% of asthmatics are exposed to fragranced products at least once a week. Also, 36.7% cannot use a public restroom if it has an air freshener or deodorizer, and 39.7% would enter a business but then leave as quickly as possible due to air fresheners or some fragranced product. Further, 35.4% of asthmatics have lost workdays or a job, in the past year, due to fragranced product exposure in the workplace. More than twice as many asthmatics would prefer that workplaces, health care facilities and health care professionals, hotels, and airplanes were fragrance-free rather than fragranced. Results from this study point to relatively simple and cost-effective ways to reduce exposure to air pollutants and health risks for asthmatics by reducing their exposure to fragranced products.Entities:
Keywords: Asthma; Fragrance; Fragranced consumer products; Health effects; Indoor air quality; Semi-volatile organic compounds; Volatile organic compounds
Year: 2017 PMID: 29391919 PMCID: PMC5773620 DOI: 10.1007/s11869-017-0536-2
Source DB: PubMed Journal: Air Qual Atmos Health ISSN: 1873-9318 Impact factor: 3.763
Demographic information
| Asthmatics | Non-asthmatics | General population | |||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| % of column total | % of general population row | ||||
| Total | 305 | 305 | 832 | 832 | 1137 |
| 100.0% | 26.8% | 100.0% | 73.2% | 100.0% | |
| Male/female | |||||
| All males | 136 | 136 | 389 | 389 | 525 |
| 44.6% | 25.9% | 46.8% | 74.1% | 46.2% | |
| All females | 169 | 169 | 443 | 443 | 612 |
| 55.4% | 27.6% | 53.2% | 72.4% | 53.8% | |
| Gender–age | |||||
| Male 18–24 | 16 | 16 | 31 | 31 | 47 |
| 5.2% | 34.0% | 3.7% | 66.0% | 4.1% | |
| Male 25–34 | 36 | 36 | 94 | 94 | 130 |
| 11.8% | 27.7% | 11.3% | 72.3% | 11.4% | |
| Male 35–44 | 42 | 42 | 94 | 94 | 136 |
| 13.8% | 30.9% | 11.3% | 69.1% | 12.0% | |
| Male 45–54 | 30 | 30 | 78 | 78 | 108 |
| 9.8% | 27.8% | 9.4% | 72.2% | 9.5% | |
| Male 55–65 | 12 | 12 | 92 | 92 | 104 |
| 3.9% | 11.5% | 11.1% | 88.5% | 9.1% | |
| Female 18–24 | 26 | 26 | 52 | 52 | 78 |
| 8.5% | 33.3% | 6.3% | 66.7% | 6.9% | |
| Female 25–34 | 40 | 40 | 95 | 95 | 135 |
| 13.1% | 29.6% | 11.4% | 70.4% | 11.9% | |
| Female 35–44 | 43 | 43 | 112 | 112 | 155 |
| 14.1% | 27.7% | 13.5% | 72.3% | 13.6% | |
| Female 45–54 | 41 | 41 | 103 | 103 | 144 |
| 13.4% | 28.5% | 12.4% | 71.5% | 12.7% | |
| Female 55–65 | 19 | 19 | 81 | 81 | 100 |
| 6.2% | 19.0% | 9.7% | 81.0% | 8.8% | |
Frequency and types of adverse health effects reported from exposure to fragranced consumer products
| Asthmatics | Non-asthmatics | General population | |
|---|---|---|---|
| 305 | 832 | 1137 | |
| 26.8% | 73.2% | 100.0% | |
| Migraine headaches | 86 | 93 | 179 |
| 28.2% | 11.2% | 15.7% | |
| Asthma attacks | 85 | 6 | 91 |
| 27.9% | 0.7% | 8.0% | |
| Neurological problems | 46 | 36 | 82 |
| 15.1% | 4.3% | 7.2% | |
| Respiratory problems | 132 | 79 | 211 |
| 43.3% | 9.5% | 18.6% | |
| Skin problems | 58 | 63 | 121 |
| 19.0% | 7.6% | 10.6% | |
| Cognitive problems | 43 | 23 | 66 |
| 14.1% | 2.8% | 5.8% | |
| Mucosal symptoms | 83 | 101 | 184 |
| 27.2% | 12.1% | 16.2% | |
| Immune system problems | 34 | 11 | 45 |
| 11.1% | 1.3% | 4.0% | |
| Gastrointestinal problems | 37 | 26 | 63 |
| 12.1% | 3.1% | 5.5% | |
| Cardiovascular problems | 30 | 20 | 50 |
| 9.8% | 2.4% | 4.4% | |
| Musculoskeletal problems | 29 | 14 | 43 |
| 9.5% | 1.7% | 3.8% | |
| Other | 4 | 15 | 19 |
| 1.3% | 1.8% | 1.7% | |
| Total | 196 | 198 | 394 |
| (One or more health problems) |
|
|
|
Demographic information for individuals reporting adverse effects from exposure to fragranced products
| Asthmatics | Non-asthmatics | General population | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Total | 196 | 196 | 198 | 198 | 394 | 394 |
| 100.0% | 64.3% | 100.0% | 23.8% | 100.0% | 34.7% | |
| Male/female | ||||||
| All males | 94 | 94 | 79 | 79 | 173 | 173 |
| 48.0% | 69.1% | 39.9% | 20.3% | 43.9% | 33.0% | |
| All females | 102 | 102 | 119 | 119 | 221 | 221 |
| 52.0% | 60.4% | 60.1% | 26.9% | 56.1% | 36.1% | |
| Gender–age | ||||||
| Male 18–24 | 8 | 8 | 6 | 6 | 14 | 14 |
| 4.1% | 50.0% | 3.0% | 19.4% | 3.6% | 29.8% | |
| Male 25–34 | 30 | 30 | 17 | 17 | 47 | 47 |
| 15.3% | 83.3% | 8.6% | 18.1% | 11.9% | 36.2% | |
| Male 35–44 | 31 | 31 | 24 | 24 | 55 | 55 |
| 15.8% | 73.8% | 12.1% | 25.5% | 14.0% | 40.4% | |
| Male 45–54 | 17 | 17 | 15 | 15 | 32 | 32 |
| 8.7% | 56.7% | 7.6% | 19.2% | 8.1% | 29.6% | |
| Male 55–65 | 8 | 8 | 17 | 17 | 25 | 25 |
| 4.1% | 66.7% | 8.6% | 18.5% | 6.3% | 24.0% | |
| Female 18–24 | 12 | 12 | 8 | 8 | 20 | 20 |
| 6.1% | 46.2% | 4.0% | 15.4% | 5.1% | 25.6% | |
| Female 25–34 | 23 | 23 | 27 | 27 | 50 | 50 |
| 11.7% | 57.5% | 13.6% | 28.4% | 12.7% | 37.0% | |
| Female 35–44 | 28 | 28 | 33 | 33 | 61 | 61 |
| 14.3% | 65.1% | 16.7% | 29.5% | 15.5% | 39.4% | |
| Female 45–54 | 27 | 27 | 26 | 26 | 53 | 53 |
| 13.8% | 65.9% | 13.1% | 25.2% | 13.5% | 36.8% | |
| Female 55–65 | 12 | 12 | 25 | 25 | 37 | 37 |
| 6.1% | 63.2% | 12.6% | 30.9% | 9.4% | 37.0% | |
Frequency and types of health problems experienced by asthmatics, non-asthmatics, and the general population from exposure to four types of fragranced consumer products
| Air fresheners or deodorizers | Scented laundry products | Scented cleaning products | Fragranced person | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asth | Non-asth | Gen Pop | Asth | Non-asth | Gen Pop | Asth | Non-asth | Gen Pop | Asth | Non-asth | Gen Pop | |
| Health problem | 125 | 107 | 232 | 88 | 54 | 142 | 129 | 95 | 224 | 141 | 127 | 268 |
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Migraines | 46 | 36 | 82 | 24 | 13 | 37 | 42 | 33 | 75 | 45 | 51 | 96 |
| 36.8% | 33.6% | 35.3% | 27.3% | 24.1% | 26.1% | 32.6% | 34.7% | 33.5% | 31.9% | 40.2% | 35.8% | |
| Asthma attacks | 49 | 4 | 53 | 27 | 1 | 28 | 42 | 4 | 46 | 41 | 3 | 44 |
| 39.2% | 3.7% | 22.8% | 30.7% | 1.9% | 19.7% | 32.6% | 4.2% | 20.5% | 29.1% | 2.4% | 16.4% | |
| Neurological | 19 | 17 | 36 | 16 | 8 | 24 | 28 | 19 | 47 | 27 | 14 | 41 |
| 15.2% | 15.9% | 15.5% | 18.2% | 14.8% | 16.9% | 21.7% | 20.0% | 21.0% | 19.1% | 11.0% | 15.3% | |
| Respiratory | 68 | 40 | 108 | 34 | 12 | 46 | 67 | 42 | 109 | 77 | 41 | 118 |
| 54.4% | 37.4% | 46.6% | 38.6% | 22.2% | 32.4% | 51.9% | 44.2% | 48.7% | 54.6% | 32.3% | 44.0% | |
| Skin | 33 | 32 | 65 | 22 | 19 | 41 | 25 | 20 | 45 | 24 | 15 | 39 |
| 26.4% | 29.9% | 28.0% | 25.0% | 35.2% | 28.9% | 19.4% | 21.1% | 20.1% | 17.0% | 11.8% | 14.6% | |
| Cognitive | 15 | 16 | 31 | 9 | 6 | 15 | 21 | 10 | 31 | 21 | 9 | 30 |
| 12.0% | 15.0% | 13.4% | 10.2% | 11.1% | 10.6% | 16.3% | 10.5% | 13.8% | 14.9% | 7.1% | 11.2% | |
| Mucosal | 37 | 49 | 86 | 27 | 21 | 48 | 35 | 48 | 83 | 40 | 58 | 98 |
| 29.6% | 45.8% | 37.1% | 30.7% | 38.9% | 33.8% | 27.1% | 50.5% | 37.1% | 28.4% | 45.7% | 36.6% | |
| Immune system | 16 | 5 | 21 | 16 | 3 | 19 | 18 | 5 | 23 | 17 | 2 | 19 |
| 12.8% | 4.7% | 9.1% | 18.2% | 5.6% | 13.4% | 14.0% | 5.3% | 10.3% | 12.1% | 1.6% | 7.1% | |
| Gastrointestinal | 18 | 13 | 31 | 20 | 9 | 29 | 17 | 15 | 32 | 21 | 10 | 31 |
| 14.4% | 12.1% | 13.4% | 22.7% | 16.7% | 20.4% | 13.2% | 15.8% | 14.3% | 14.9% | 7.9% | 11.6% | |
| Cardiovascular | 18 | 12 | 30 | 11 | 4 | 15 | 16 | 10 | 26 | 15 | 5 | 20 |
| 14.4% | 11.2% | 12.9% | 12.5% | 7.4% | 10.6% | 12.4% | 10.5% | 11.6% | 10.6% | 3.9% | 7.5% | |
| Musculoskeletal | 19 | 8 | 27 | 21 | 2 | 23 | 13 | 10 | 23 | 15 | 2 | 17 |
| 15.2% | 7.5% | 11.6% | 23.9% | 3.7% | 16.2% | 10.1% | 10.5% | 10.3% | 10.6% | 1.6% | 6.3% | |
| Other | 2 | 6 | 8 | 1 | 3 | 4 | 2 | 2 | 4 | 2 | 5 | 7 |